BMEA241018C22500
- 0.10
- 0.000.00%
Biomea Fusion Newsroom
Biomea Fusion Analyst Ratings
Biomea Fusion Initiated With a Buy at EF Hutton
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $10
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $10 to $60
Biomea Fusion Price Target Raised to $41.00/Share From $21.00 by Scotiabank
Biomea Upgraded by Analysts After FDA Lifts Clinical Hold
Biomea Fusion Is Maintained at Equal-Weight by Barclays
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $9 to $60
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)
Piper Sandler Remains a Buy on Biomea Fusion (BMEA)
Buy Rating Affirmed for Biomea Fusion With Promising BMF-219 Clinical and Regulatory Developments
Biomea Fusion Upgraded to Buy From Hold at Truist
Biomea Fusion Analyst Ratings
Balanced Outlook With a Hold Rating for Biomea Fusion Amidst Upcoming Milestones and Clinical Developments
Truist Sees Fair Value of $20-$50 per Share After Biomea Fusion Hold Lifted
Truist Financial Maintains Biomea Fusion(BMEA.US) With Hold Rating
Biomea Fusion Initiated at Overweight by Capital One
Capital One Financial Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $25
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $22